COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

European Dyspnoea Survey in the EMergency Departments (EuroDEM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02060799
Recruitment Status : Completed
First Posted : February 12, 2014
Last Update Posted : December 18, 2014
Information provided by (Responsible Party):
Said LARIBI, MD, PhD., Hopital Lariboisière

Brief Summary:

Braunwald defines dyspnoea as an abnormally uncomfortable awareness of breathing. Breathing discomfort, and its varying degrees of severity, is the one of the most disturbing symptoms patients can experience; and it is one of the main complaints in the patients presenting to the Emergency Department (ED). Dyspnea has a variety of underlying etiologies, like cardiac, pulmonary or metabolic etiologies or a combination of them, since several diseases can cause dyspnea like for instance heart failure (HF), asthma and chronic obstructive pulmonary disease (COPD).

Acute heart failure syndrome (AHFS) is collectively defined as a gradual or rapid change in heart failure (HF) signs and symptoms resulting in a need for urgent therapy. Heart failure (HF) is one of the most important causes of morbidity and mortality in the industrialized world. The prevalence of symptomatic HF is estimated to range from 0.4 to 2.0% in general European population. The incidence increases rapidly with age, and in Europe. Characteristics, clinical presentation, treatment, and outcomes of HF patients admitted to hospital have been adequately described, in Europe and in the United States. The Euro Heart Failure Survey (EHFS) I with 11 327 patients described the demographics of acutely hospitalized HF patients. The ADHERE registry has data on over 100 000 hospitalizations for AHF from the USA. In-hospital mortality was 4 and 7%, in ADHERE and EHFS I, respectively.

This same sensation of breathlessness is what also drives patients with asthma and chronic obstructive pulmonary disease (COPD) to the ED. Chronic obstructive pulmonary disease (COPD) exacerbation accounts for approximately 1.5 million ED visits in the United States per year. It is the third most common cause of hospitalization, with an estimated 726 000 hospitalizations in 2000 in the USA. Previous studies have demonstrated important differences between guideline recommendations and actual management of COPD exacerbation, either in the ED or during hospitalization.

The diagnosis in front of a dyspneic patient in the ED remains a challenge, because of a low sensitivity of the clinical signs associated with the aging of the population and the variety of underlying diseases. Little is known about the Epidemiology of dyspneic patients in the ED at the European level. Diagnosis, prevalence and treatment of the patients may vary among European countries.

Condition or disease
Dyspnea Emergencies

Detailed Description:


  • Epidemiologic description of patients presenting to the ED with shortness of breath as main complaint.
  • Description of current management in the ED of patients presenting to the ED with shortness of breath as main complaint.


  • Sub analysis of ED discharged patients versus admitted patients for characteristics, comparison to recommended care and re-ED visit.
  • Determine clinical and/or biological criteria to distinguish between:

    • Patients who are treated as outpatients and admitted patients.
    • Patients hospitalized in ward and patients admitted to intensive care units (CCU and ICU)
  • Prognostic prediction, using clinical and biochemical data
  • To determine if ED patients treated for acute heart failure differ from those admitted to hospital.
  • Comparison of European data characteristics, investigation, treatment and outcome to similar data in other part of the world.

Layout table for study information
Study Type : Observational [Patient Registry]
Actual Enrollment : 2156 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 30 Days
Official Title: European Dyspnoea Survey in the EMergency Departments
Study Start Date : February 2014
Actual Primary Completion Date : March 2014
Actual Study Completion Date : November 2014

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. All cause mortality [ Time Frame: 30 days ]
    All cause mortality will be evaluated 30 days after ED visit.

Secondary Outcome Measures :
  1. All cause rehospitalization [ Time Frame: 30 days ]

Other Outcome Measures:
  1. ED visit [ Time Frame: 30 days ]
    New ED visit during follow-up

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Consecutive patients presenting to the Emergency Department with Dyspnea as main complaint during the study period.

Inclusion Criteria:

  • Consecutive patients presenting to the Emergency Department with Dyspnea as main complaint
  • 18 years or older

Exclusion Criteria:

  • No acceptance to participate from the patient

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02060799

Layout table for location information
Country: Belgium
Brussels, Belgium
Country: Finland
Helsinki, Finland
Country: France
Paris, France
Country: Germany
Nuremberg, Germany
Country: Italy
Rome, Italy
Country: Netherlands
Amsterdam, Netherlands
Country: Romania
Cluj Napoca, Romania
Country: Spain
Santander, Spain
Country: Turkey
Ankara, Turkey
United Kingdom
Country: United Kingdom
Manchester, United Kingdom
Sponsors and Collaborators
Hopital Lariboisière
Layout table for investigator information
Principal Investigator: Said LARIBI, MD, PhD Lariboisière Hospital, EuSEM
Additional Information:

Layout table for additonal information
Responsible Party: Said LARIBI, MD, PhD., Principal Investigator, Hopital Lariboisière Identifier: NCT02060799    
Other Study ID Numbers: HLariboisiere
First Posted: February 12, 2014    Key Record Dates
Last Update Posted: December 18, 2014
Last Verified: December 2014
Keywords provided by Said LARIBI, MD, PhD., Hopital Lariboisière:
Emergency Service, Hospital
Fatal Outcome
Additional relevant MeSH terms:
Layout table for MeSH terms
Disease Attributes
Pathologic Processes
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms